glp-1/gip dual agonist weight loss The Emerging Role of GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction Unveiling Tirzepatide's Therapeutic Spectrum: A
Description
Melanie Jay, who studies the treatment and prevention of obesity at NYU Langone Health
[DOI] [PMC free article] [PubMed] [Google Scholar] 71
The most common adverse effects were also gastrointestinal and dose-related and were partially mitigated with a lower starting dose (2 mg vs
Diabetes Obes Metab (2018) 20(1):2158
The glucose-dependent effects theory highlights that both hormones work in glucose-dependent ways but with different patterns
In the 2022 SURMOUNT-1 study published in NEJM, three doses of tirzepatide were compared with placebo (1:1:1:1) to determine effects on percent weight change over the course of 72 weeks
